{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T08:46:25Z","timestamp":1773737185709,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012669","name":"Natural Science Foundation Project of Chongqing, Chongqing Science and Technology Commission","doi-asserted-by":"publisher","award":["cstc2020jcyjmsxmX0256"],"award-info":[{"award-number":["cstc2020jcyjmsxmX0256"]}],"id":[{"id":"10.13039\/501100012669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012669","name":"Natural Science Foundation Project of Chongqing, Chongqing Science and Technology Commission","doi-asserted-by":"publisher","award":["cstc2018jcyjAX0688"],"award-info":[{"award-number":["cstc2018jcyjAX0688"]}],"id":[{"id":"10.13039\/501100012669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000173"],"award-info":[{"award-number":["82000173"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Direct"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The outcome of Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) remain dismal despite the development of treatment. Targeted therapy is gaining more and more attention in improving prognosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Expression of <jats:italic>BRAF<\/jats:italic> was analyzed by RT-qPCR in AML and MDS patients. Cells viability treated by drugs was measured by CCK-8 assay. Network pharmacology and RNA-sequence were used to analyze the mechanism of drugs and verified in vitro and xenograft tumor model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Here we showed that <jats:italic>BRAF<\/jats:italic> was overexpressed in AML and MDS patients, and correlated with poor prognosis. The <jats:italic>BRAF<\/jats:italic> inhibitor-Vemurafenib (VEM) could significantly induce senescence, proliferation inhibition and apoptosis in AML cells, which can be enhanced by Bortezomib (BOR). This inhibitory effect was also verified in CD34\u2009+\u2009cells derived from AML patients. Mechanistically, we showed that VEM combined with BOR could turn on HIPPO signaling pathway, thereby inducing cellular senescence in AML cells and xenograft mouse.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Taken together, our findings demonstrate a significant upregulation of <jats:italic>BRAF<\/jats:italic> expression in AML and MDS patients, which is associated with unfavorable clinical outcomes. We also discovered that the <jats:italic>BRAF<\/jats:italic> inhibitor Vemurafenib induces cellular senescence through activation of the HIPPO signaling pathway. Analysis of <jats:italic>BRAF<\/jats:italic> expression holds promise as a prognostic indicator and potential therapeutic target for individuals with AML and MDS. <\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13062-023-00451-0","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T15:05:48Z","timestamp":1704380748000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Vemurafenib induces senescence in acute myeloid leukemia and myelodysplastic syndrome by activating the HIPPO signaling pathway: implications for potential targeted therapy"],"prefix":"10.1186","volume":"19","author":[{"given":"Qiao","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiamin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingsong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duo","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenqiong","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Rodrigues-Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxiang","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabien","family":"Guidez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"issue":"1","key":"451_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-00908-z","volume":"13","author":"M Yi","year":"2020","unstructured":"Yi M, et al. \"The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. J Hematol Oncol. 2020;13(1):1\u201316.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"451_CR2","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1182\/bloodadvances.2021005335","volume":"6","author":"D Mart\u00ednez-Cuadr\u00f3n","year":"2022","unstructured":"Mart\u00ednez-Cuadr\u00f3n D, et al. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. Blood Adv. 2022;6(4):1278\u201395. https:\/\/doi.org\/10.1182\/bloodadvances.2021005335.","journal-title":"Blood Adv"},{"issue":"4","key":"451_CR3","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/s41375-020-0997-4","volume":"35","author":"S Yun","year":"2021","unstructured":"Yun S, et al. Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML). Leukemia. 2021;35(4):1145\u201355. https:\/\/doi.org\/10.1038\/s41375-020-0997-4.","journal-title":"Leukemia"},{"issue":"3","key":"451_CR4","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.3892\/etm.2020.8454","volume":"19","author":"YJ Guo","year":"2020","unstructured":"Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y, Hu LL. ERK\/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 2020;19(3):1997\u20132007. https:\/\/doi.org\/10.3892\/etm.2020.8454.","journal-title":"Exp Ther Med"},{"key":"451_CR5","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202201445","author":"D Romano","year":"2022","unstructured":"Romano D, et al. \"Proteasomal down-regulation of the proapoptotic MST2 pathway contributes to BRAF inhibitor resistance in melanoma. Life Sci Alliance. 2022. https:\/\/doi.org\/10.26508\/lsa.202201445.","journal-title":"Life Sci Alliance"},{"key":"451_CR6","doi-asserted-by":"publisher","first-page":"658481","DOI":"10.3389\/fcell.2021.658481","volume":"9","author":"YS Cho","year":"2021","unstructured":"Cho YS, Jiang J. Hippo-independent regulation of Yki\/Yap\/Taz: a non-canonical view. Front Cell Dev Biol. 2021;9:658481.","journal-title":"Front Cell Dev Biol"},{"key":"451_CR7","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.canlet.2021.03.006","volume":"507","author":"S Mohajan","year":"2021","unstructured":"Mohajan S, et al. Hippo pathway: regulation, deregulation and potential therapeutic targets in cancer. Cancer Lett. 2021;507:112\u201323.","journal-title":"Cancer Lett"},{"key":"451_CR8","doi-asserted-by":"publisher","first-page":"111280","DOI":"10.1016\/j.mad.2020.111280","volume":"189","author":"D Elster","year":"2020","unstructured":"Elster D, von Eyss B. Hippo signaling in regeneration and aging. Mech Ageing Dev. 2020;189:111280.","journal-title":"Mech Ageing Dev"},{"issue":"12","key":"451_CR9","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1038\/sj.leu.2404009","volume":"19","author":"DH Christiansen","year":"2005","unstructured":"Christiansen DH, et al. Mutations of genes in the receptor tyrosine kinase (RTK)\/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2005;19(12):2232\u201340.","journal-title":"Leukemia"},{"issue":"2","key":"451_CR10","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/sj.leu.2405078","volume":"22","author":"J Pedersen-Bjergaard","year":"2008","unstructured":"Pedersen-Bjergaard J, et al. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2008;22(2):240\u20138.","journal-title":"Leukemia"},{"issue":"1","key":"451_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1530\/ERC-17-0182","volume":"25","author":"K Tsumagari","year":"2018","unstructured":"Tsumagari K, et al. Bortezomib sensitizes thyroid cancer to BRAF inhibitor in vitro and in vivo. Endocr Relat Cancer. 2018;25(1):99\u2013109.","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"451_CR12","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/1346-8138.12950","volume":"42","author":"MR Roh","year":"2015","unstructured":"Roh MR, et al. Low-concentration vemurafenib induces the proliferation and invasion of human HaCaT keratinocytes through mitogen-activated protein kinase pathway activation. J Dermatol. 2015;42(9):881\u20138.","journal-title":"J Dermatol"},{"issue":"20","key":"451_CR13","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544.","journal-title":"Blood"},{"issue":"4","key":"451_CR14","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347. https:\/\/doi.org\/10.1182\/blood-2016-08-733196.","journal-title":"Blood"},{"issue":"2","key":"451_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3760\/cma.j.issn.0253-2727.2019.02.001","volume":"40","author":"Chinese Society of Hematology","year":"2019","unstructured":"Chinese Society of Hematology. Chinese Medical Association. Zhonghua Xue Ye Xue Za Zhi. 2019;40(2):89\u201397. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2019.02.001.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"451_CR16","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488\u201398.","journal-title":"N Engl J Med"},{"issue":"5","key":"451_CR17","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41568-021-00435-0","volume":"22","author":"EC Cheung","year":"2022","unstructured":"Cheung EC, Vousden KH. The role of ROS in tumour development and progression. Nat Rev Cancer. 2022;22(5):280\u201397.","journal-title":"Nat Rev Cancer"},{"issue":"18","key":"451_CR18","first-page":"3563","volume":"121","author":"O Abdel-Wahab","year":"2013","unstructured":"Abdel-Wahab O, Levine RL. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood J Am Soc Hematol. 2013;121(18):3563\u201372.","journal-title":"Blood J Am Soc Hematol"},{"issue":"2","key":"451_CR19","doi-asserted-by":"publisher","first-page":"e390","DOI":"10.1038\/bcj.2016.3.PMID:26849011;PMCID:PMC4771966","volume":"6","author":"H Bower","year":"2016","unstructured":"Bower H, Andersson TM, Bj\u00f6rkholm M, Dickman PW, Lambert PC, Derolf \u00c5R. Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of life. Blood Cancer J. 2016;6(2):e390. https:\/\/doi.org\/10.1038\/bcj.2016.3.PMID:26849011;PMCID:PMC4771966.","journal-title":"Blood Cancer J"},{"issue":"1","key":"451_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3390\/cancers12010103","volume":"12","author":"P Zjablovskaja","year":"2019","unstructured":"Zjablovskaja P, Florian MC. Acute myeloid leukemia: aging and epigenetics. Cancers. 2019;12(1):103.","journal-title":"Cancers"},{"issue":"6","key":"451_CR21","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","volume":"153","author":"C Lopez-Otin","year":"2013","unstructured":"Lopez-Otin C, et al. The hallmarks of aging. Cell. 2013;153(6):1194\u2013217.","journal-title":"Cell"},{"issue":"24","key":"451_CR22","first-page":"24737","volume":"12","author":"EA Maria Hernandez-Valladares","year":"2020","unstructured":"Maria Hernandez-Valladares EA, Berven F, Selheim F, Bruserud \u00d8. Biological characteristics of aging in human acute myeloid leukemia cells: the possible importance of aldehyde dehydrogenase, the cytoskeleton and altered transcriptional regulation. Aging. 2020;12(24):24737.","journal-title":"Aging"},{"issue":"18","key":"451_CR23","doi-asserted-by":"publisher","first-page":"4484","DOI":"10.3390\/ijms20184484","volume":"20","author":"E Molnar","year":"2019","unstructured":"Molnar E, et al. Long-term Vemurafenib exposure induced alterations of cell phenotypes in melanoma: increased cell migration and its association with EGFR expression. Int J Mol Sci. 2019;20(18):4484.","journal-title":"Int J Mol Sci"},{"key":"451_CR24","doi-asserted-by":"publisher","first-page":"794216","DOI":"10.3389\/fonc.2022.794216","volume":"12","author":"H Li","year":"2022","unstructured":"Li H, et al. Dimethyl fumarate combined with vemurafenib enhances anti-melanoma efficacy via inhibiting the Hippo\/YAP, NRF2-ARE, and AKT\/mTOR\/ERK pathways in A375 melanoma cells. Front Oncol. 2022;12:794216.","journal-title":"Front Oncol"},{"key":"451_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev-med-090514-030732","volume":"67","author":"W Fiskus","year":"2016","unstructured":"Fiskus W, Mitsiades N. B-Raf inhibition in the clinic: present and future. Annu Rev Med. 2016;67:29\u201343.","journal-title":"Annu Rev Med"},{"issue":"19","key":"451_CR26","doi-asserted-by":"publisher","first-page":"5089","DOI":"10.1158\/0008-5472.CAN-20-3761","volume":"81","author":"S Maifrede","year":"2021","unstructured":"Maifrede S, Skorski T, et al. TET2 and DNMT3A Mutations exert divergent effects on DNA repair and sensitivity of leukemia cells to PARP inhibitors. Cancer Res. 2021;81(19):5089\u2013101. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3761.","journal-title":"Cancer Res"},{"key":"451_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1530\/ERC-17-0182","volume":"25","author":"K Tsumagari","year":"2018","unstructured":"Tsumagari K, et al. Bortezomib sensitizes thyroid cancer to BRAF inhibitor in vitro and in vivo. Endocrine-Relat Cancer. 2018;25:99\u2013109. https:\/\/doi.org\/10.1530\/ERC-17-0182.","journal-title":"Endocrine-Relat Cancer"},{"key":"451_CR28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3892\/etm.2021.9628","volume":"21","author":"V Mpakou","year":"2021","unstructured":"Mpakou V, et al. Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line Kasumi-1. Exp Ther Med. 2021;21:195. https:\/\/doi.org\/10.3892\/etm.2021.9628.","journal-title":"Exp Ther Med"},{"key":"451_CR29","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.3324\/haematol.2019.220962","volume":"105","author":"R Aplenc","year":"2020","unstructured":"Aplenc R, et al. Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children\u2019s Oncology Group. Haematologica. 2020;105:1879\u201386. https:\/\/doi.org\/10.3324\/haematol.2019.220962.","journal-title":"Haematologica"},{"issue":"3","key":"451_CR30","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/ng.3218","volume":"47","author":"L Lin","year":"2015","unstructured":"Lin L, et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015;47(3):250\u20136. https:\/\/doi.org\/10.1038\/ng.3218.","journal-title":"Nat Genet"},{"issue":"8","key":"451_CR31","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1002\/ijc.27316","volume":"130","author":"H Rayess","year":"2012","unstructured":"Rayess H, et al. Cellular senescence and tumor suppressor gene p16. Int J Cancer. 2012;130(8):1715\u201325.","journal-title":"Int J Cancer"},{"key":"451_CR32","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s11427-019-1629-6","volume":"63","author":"L Yuan","year":"2020","unstructured":"Yuan L, et al. Cellular senescence: from anti-cancer weapon to anti-aging target. Sci China Life Sci. 2020;63:332\u201342. https:\/\/doi.org\/10.1007\/s11427-019-1629-6.","journal-title":"Sci China Life Sci"},{"key":"451_CR33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nm.4010","volume":"22","author":"J Chang","year":"2016","unstructured":"Chang J, et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med. 2016;22:78\u201383. https:\/\/doi.org\/10.1038\/nm.4010.","journal-title":"Nat Med"},{"issue":"13","key":"451_CR34","doi-asserted-by":"publisher","first-page":"12750","DOI":"10.18632\/aging.103177","volume":"12","author":"H Yang","year":"2020","unstructured":"Yang H, et al. Navitoclax (ABT263) reduces inflammation and promotes chondrogenic phenotype by clearing senescent osteoarthritic chondrocytes in osteoarthritis. Aging. 2020;12(13):12750\u201370. https:\/\/doi.org\/10.18632\/aging.103177.","journal-title":"Aging"},{"key":"451_CR35","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.phrs.2019.03.018","volume":"143","author":"YT Yeung","year":"2019","unstructured":"Yeung YT, et al. Dysregulation of the Hippo pathway signaling in aging and cancer. Pharmacol Res. 2019;143:151\u201365.","journal-title":"Pharmacol Res"},{"issue":"19","key":"451_CR36","doi-asserted-by":"publisher","first-page":"5798","DOI":"10.1111\/febs.16091","volume":"289","author":"H Kwon","year":"2022","unstructured":"Kwon H, et al. Role of the Hippo pathway and mechanisms for controlling cellular localization of YAP\/TAZ. FEBS J. 2022;289(19):5798\u2013818.","journal-title":"FEBS J"},{"issue":"1\u20132","key":"451_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11010-019-03667-9","volume":"467","author":"S Yang","year":"2020","unstructured":"Yang S, Lian G. ROS and diseases: role in metabolism and energy supply. Mol Cell Biochem. 2020;467(1\u20132):1\u201312.","journal-title":"Mol Cell Biochem"}],"container-title":["Biology Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-023-00451-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13062-023-00451-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-023-00451-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T15:07:49Z","timestamp":1704380869000},"score":1,"resource":{"primary":{"URL":"https:\/\/biologydirect.biomedcentral.com\/articles\/10.1186\/s13062-023-00451-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["451"],"URL":"https:\/\/doi.org\/10.1186\/s13062-023-00451-0","relation":{},"ISSN":["1745-6150"],"issn-type":[{"value":"1745-6150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]},"assertion":[{"value":"15 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments were approved by the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University. (2021-684\/2021-601).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}